Highlights of This Issue 495

EDITORIAL

497  A Vision from the New Editor-in-Chief
Beverly A. Teicher

REVIEW

498  What CAR Will Win the CD19 Race?
Alfonso Quintás-Cardama

SMALL MOLECULE THERAPEUTICS

507  Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Alexandre Chlenski, Chanyoung Park, Marija Dobratic, Helen R. Salwen, Brian Budke, Jae-Hyun Park, Ryan Miller, Mark A. Applebaum, Emma Wilkinson, Yusuke Nakamura, Philip P. Connell, and Susan L. Cohn

517  The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway

531  First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

556  The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active Site Catalytic Metals in PPP5C
Brandon M. D’Arcy, Mark R. Swingle, Cinta M. Papke, Kevin A. Abney, Erin S. Bouska, Aishwarya Prakash, and Richard E. Honkanen

567  A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
Ronja Bjørnstad, Reidun Aesoy, Øystein Bruserud, Annette K. Brenner, Francis Giraud, Tara Helen Dowling, Gro Gausdal, Pascale Moreau, Stein Ove Døskeland, Fabrice Anizon, and Lars Herfindal

LARGE MOLECULE THERAPEUTICS

579  Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis
Divya Ramchandani, Seung Koo Lee, Shira Youmoutb, Myung Shin Han, Ching-Hsuan Tung, and Vivek Mittal

592  Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin
Kevin A. Carter, Dandan Luo, Jumin Geng, Stephen T. Stern, and Jonathan F. Lovell

602  Chemically Modified Antisense Oligonucleotide Against ARL14C Inhibits Primary and Metastatic Liver Tumor Growth

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

613  TGFB Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Daniel R. Princepe, Alex Park, Matthew J. Dorman, Sandeep Kumar, Navin Viswakarma, Jonathan Rubin, Carolina Torres, Ronald McKinney, Hidayatullah G. Munshi, Paul J. Grippo, and Ajay Rana
ABOUT THE COVER

TGFβ signaling is critical for the evasion of immune surveillance in pancreatic ductal adenocarcinoma (PDAC). In this issue, Principe and colleagues explored the efficacy of combined TGFβ and immune checkpoint inhibition in murine PDAC. Tumor bearing mice were treated with the TGFBR1 inhibitor Galunisertib and/or anti-PD-1. The combination significantly reduced tumor burden, increased T-cell infiltration, and improved survival. In the corresponding image, they stained the pancreas of a dual-treated animal for the duct marker CK19 (green), and cytotoxic surrogate Granzyme B (red). This affirms an improved anti-tumor immune response, and suggests that agents such as Galunisertib may potentiate immune checkpoint inhibition in PDAC.
# Molecular Cancer Therapeutics

## 18 (3)


## Updated version

Access the most recent version of this article at:

http://mct.aacrjournals.org/content/18/3

## E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

## Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

## Permissions

To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/18/3. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.